A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

NCT05528861 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

127

Enrollment

INDUSTRY

Sponsor class

Stopped No longer pursuing development

Conditions

Chronic Spontaneous Urticaria

Interventions

DRUG: Lirentelimab (AK002)
OTHER: Placebo

Sponsor

Allakos Inc.